Every story in this section, newest first — page 246 of 373.
Fennec Pharmaceuticals (NASDAQ:FENC) today reported its financial results for the fourth quarter and full year ended December 31, 2025, highlighting a year of aggressive commercial scaling and a total recapitalization of the company’s balance sheet.
Achieve Life Sciences (NASDAQ:ACHV) today reported its financial results for the fourth quarter and full year ended December 31, 2025, alongside a series of transformative regulatory and operational updates for its lead smoking cessation candidate, cytisinicline.
Karyopharm Therapeutics (NASDAQ:KPTI) today announced topline results from its global Phase 3 SENTRY clinical trial (n=353) evaluating the XPO1 inhibitor selinexor in combination with ruxolitinib (Jakafi®) for the frontline treatment of patients with myelofibrosis.
LightInTheBox Holding (NYSE:LITB) today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2025, marking a definitive shift from high-volume scaling to high-margin profitability.
VersaBank (NASDAQ:VBNK) today announced it has reached a definitive agreement to sell the assets associated with its sole U.S. retail branch in Holdingford, Minnesota, to Stearns Bank National Association.
The Buckle (NYSE:BKE) today announced that its Board of Directors has authorized a quarterly cash dividend of $0.35 per share.
BioNTech (NASDAQ:BNTX) announced today its comprehensive participation in the European Lung Cancer Congress (ELCC) 2026, where the company will present updated data across its diversified lung cancer portfolio.
UTStarcom (NASDAQ:UTSI) today reported its unaudited financial results for the six months and full year ended December 31, 2025, revealing a challenging fiscal year defined by a significant contraction in its primary geographic markets.
Radiopharm Theranostics (NASDAQ:RADX) today released a highly encouraging second interim data update from its ongoing U.S. Phase 2b clinical trial evaluating RAD 101, a novel FASN-targeting small-molecule imaging agent.
G. Willi-Food International (NASDAQ:WILC) today announced its financial results for the fiscal year ended December 31, 2025, revealing a year of significant margin expansion and record bottom-line performance.
Borr Drilling (NYSE:BORR) announced today that it has entered into definitive agreements to acquire five premium jack-up rigs from Fontis Finance for a total purchase price of $287 million.
AerCap Holdings (NYSE:AER), the world’s largest aircraft lessor, has announced the signing of lease agreements with Ethiopian Airlines for two Boeing 777-300ERSF converted freighters.
Hesai Group (NASDAQ:HSAI) today announced record financial results for the fourth quarter and full year ended December 31, 2025.
Smithfield Foods (NASDAQ:SFD) today reported record financial results for fiscal year 2025, ended December 28, 2025, marking a period of significant operational recovery and strategic pivot.
Cheetah Mobile (NYSE:CMCM) today reported unaudited financial results for the full year ended December 31, 2025, marking a definitive milestone in its multi-year strategic pivot toward artificial intelligence.
Vertiv Holdings (NYSE:VRT) today announced it has reached an agreement to acquire ThermoKey, a privately held Italian manufacturer specializing in heat-rejection and heat-exchange technology.
Perfect Corp. (NYSE:PERF) announced today that its Board of Directors has formed a special committee of three independent, disinterested directors to evaluate a preliminary "going-private" proposal.
Smith-Midland (NASDAQ:SMID) today provided a preliminary look at its fourth quarter and full-year 2025 performance, signaling what is expected to be the most profitable year in the company’s history.
Cadeler (NYSE:CDLR) today published its anual report for the fiscal year ended December 31, 2025, detailing a period of unprecedented scale and financial outperformance.
Regeneron Pharmaceuticals (NASDAQ:REGN) and Sanofi today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Dupixent (dupilumab) for the treatment of adults with moderate-to-severe bullous pemphigoid (BP) whose disease is not adequately controlled by existing therapies.
Pharming Group (NASDAQ:PHAR) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted marketing approval for Joenja (leniolisib) as the first targeted treatment for activated phosphoinositide 3-kinase delta syndrome (APDS).
Corvex (NASDAQ:MOVE) today announced the successful completion of its all-stock merger with Movano, marking a definitive strategic pivot for the entity.
Pyxis Oncology (NASDAQ:PYXS), a clinical-stage biopharmaceutical company focused on next-generation therapeutics for difficult-to-treat cancers, announced it has completed target enrollment of approximately 40 patients in the Phase 1 monotherapy dose-expansion cohort of micvotabart pelidotin (MICVO) in patients with second-line or later recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
Solo Brands (NYSE:SBDS) today provided its financial outlook for fiscal year 2026, signaling a strategic pivot toward bottom-line health over top-line volume.
